Healthcare (Commonwealth Union) – The pioneering work done by Emmanuelle Charpentier of France and Jennifer Doudna of the USA for the CRISPR-Cas9 genome-editing tool paved the way for key research into molecular biology. CRISPR-Cas9 was a key transformer for gene editing by making it simpler, specific and more economical.
Researchers at the University of Virginia (UVA) School of Medicine have successfully applied a cutting-edge gene-editing approach to fix the fundamental genetic defect responsible for a severe form of epilepsy in laboratory mice. Researchers of the study stated that this advancement may pave the way for future therapies and potential cures.
Manoj Patel of UVA’s Department of Anesthesiology and the UVA Brain Institute pointed out that traditionally, treatments have focused on managing the downstream consequences of genetic mutations and now, they have the ability to correct the mutations themselves, addressing disease at its source.
He further indicated that base editing opens new possibilities for treating a wide range of genetic disorders, not just epilepsy, and could greatly enhance patients’ quality of life.
Patel and his team targeted and corrected the DNA mutation responsible for SCN8A developmental and epileptic encephalopathy, a severe inherited condition linked to seizures, impaired learning and movement, and in some cases, sudden death. The study was supported by the National Institutes of Health, the UVA Brain Institute, and the Ivy Biomedical Innovation Fund.
The results indicate that directly repairing disease-causing genetic mutations could represent a promising new direction for treating severe inherited epilepsies and other genetic diseases.
Targeting the disease at its origin is an ideal case scenario.SCN8A-related epilepsy is an uncommon disorder, occurring in about 1 in 56,000 births and representing roughly 1% of all epilepsy cases. Researchers suspect that a number of cases remain undiagnosed. It is caused by a genetic mutation that allows excess sodium to flow into brain cells, causing them to become excessively active. This abnormal activity can trigger difficult-to-control seizures, along with delays in physical and cognitive development.
Although symptoms usually emerge in early infancy, the condition can range widely in severity. In its most extreme forms, it is associated with a heightened risk of sudden, unexpected death.
Given the seriousness of the disorder and the frequent resistance of seizures to standard medications, Patel and colleagues focused on addressing the root genetic cause in search of more effective therapies. They employed base editing, a highly precise gene-editing method that enables single-letter changes in DNA.
This level of accuracy helps minimise unintended effects sometimes seen with other gene-editing techniques. Using this approach in laboratory mice, the researchers were able to correct the mutation, which either completely stopped seizures or significantly reduced them, while also improving survival rates. The treated mice showed better movement and reduced anxiety-like behaviours, indicators that suggest potential improvements in brain function and cognition.
“This shows that the devastating impact of the mutation is not permanent – and can be reversed,” explained Caeley Reever, the lead researcher for the project. “We were able to effectively ‘cure’ mice carrying this specific gene mutation – a mutation that is known to cause epilepsy in some children.”
Although further studies are required before this approach can be applied in humans, Patel notes that the results are highly promising and could open new possibilities for treating not only SCN8A-related epilepsy but also other inherited forms of the disorder.
Patel indicated that recent progress in gene therapy holds considerable promise for people with genetic conditions.
He further pointed out that rather than focusing solely on the symptoms or downstream effects, these methods allow us to directly target the root cause—the disease-causing genetic mutation itself—with genuine potential for a cure.
